PMID- 18191732
OWN - NLM
STAT- MEDLINE
DCOM- 20080205
LR  - 20220316
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Linking)
VI  - 51
IP  - 2
DP  - 2008 Jan 15
TI  - Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic 
      patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a 
      randomized, controlled, observer-blinded trial.
PG  - 103-12
LID - 10.1016/j.jacc.2007.09.036 [doi]
AB  - OBJECTIVES: We tested the hypothesis that intravenous iron improves exercise 
      tolerance in anemic and nonanemic patients with symptomatic chronic heart failure 
      (CHF) and iron deficiency. BACKGROUND: Anemia is common in heart failure. Iron 
      metabolism is disturbed, and administration of iron might improve both symptoms 
      and exercise tolerance. METHODS: We randomized 35 patients with CHF (age 64 +/- 
      13 years, peak oxygen consumption [pVO2] 14.0 +/- 2.7 ml/kg/min) to 16 weeks of 
      intravenous iron (200 mg weekly until ferritin >500 ng/ml, 200 mg monthly 
      thereafter) or no treatment in a 2:1 ratio. Ferritin was required to be <100 
      ng/ml or ferritin 100 to 300 ng/ml with transferrin saturation <20%. Patients 
      were stratified according to hemoglobin levels (<12.5 g/dl [anemic group] vs. 
      12.5 to 14.5 g/dl [nonanemic group]). The observer-blinded primary end point was 
      the change in absolute pVO2. RESULTS: The difference (95% confidence interval 
      [CI]) in the mean changes from baseline to end of study between the iron and 
      control groups was 273 (151 to 396) ng/ml for ferritin (p < 0.0001), 0.1 (-0.8 to 
      0.9) g/dl for hemoglobin (p = 0.9), 96 (-12 to 205) ml/min for absolute pVO2 (p = 
      0.08), 2.2 (0.5 to 4.0) ml/kg/min for pVO2/kg (p = 0.01), 60 (-6 to 126) s for 
      treadmill exercise duration (p = 0.08), -0.6 (-0.9 to -0.2) for New York Heart 
      Association (NYHA) functional class (p = 0.007), and 1.7 (0.7 to 2.6) for patient 
      global assessment (p = 0.002). In anemic patients (n = 18), the difference (95% 
      CI) was 204 (31 to 378) ml/min for absolute pVO2 (p = 0.02), and 3.9 (1.1 to 6.8) 
      ml/kg/min for pVO2/kg (p = 0.01). In nonanemic patients, NYHA functional class 
      improved (p = 0.06). Adverse events were similar. CONCLUSIONS: Intravenous iron 
      loading improved exercise capacity and symptoms in patients with CHF and evidence 
      of abnormal iron metabolism. Benefits were more evident in anemic patients. 
      (Effect of Intravenous Ferrous Sucrose on Exercise Capacity in Chronic Heart 
      Failure; http://www.clinicaltrials.gov/ct/show/NCT00125996; NCT00125996).
FAU - Okonko, Darlington O
AU  - Okonko DO
AD  - Clinical Cardiology, NHLI, Imperial College London, London, United Kingdom. 
      d.okonko@imperial.ac.uk
FAU - Grzeslo, Agnieszka
AU  - Grzeslo A
FAU - Witkowski, Tomasz
AU  - Witkowski T
FAU - Mandal, Amit K J
AU  - Mandal AK
FAU - Slater, Robert M
AU  - Slater RM
FAU - Roughton, Michael
AU  - Roughton M
FAU - Foldes, Gabor
AU  - Foldes G
FAU - Thum, Thomas
AU  - Thum T
FAU - Majda, Jacek
AU  - Majda J
FAU - Banasiak, Waldemar
AU  - Banasiak W
FAU - Missouris, Constantinos G
AU  - Missouris CG
FAU - Poole-Wilson, Philip A
AU  - Poole-Wilson PA
FAU - Anker, Stefan D
AU  - Anker SD
FAU - Ponikowski, Piotr
AU  - Ponikowski P
LA  - eng
SI  - ClinicalTrials.gov/NCT00125996
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Ferric Compounds)
SB  - IM
MH  - Aged
MH  - Analysis of Variance
MH  - Anemia, Iron-Deficiency/complications/diagnosis/*drug therapy/mortality
MH  - Chronic Disease
MH  - Confidence Intervals
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Exercise Tolerance/*drug effects
MH  - Female
MH  - Ferric Compounds/*administration & dosage
MH  - Follow-Up Studies
MH  - Heart Failure/complications/diagnosis/*drug therapy/mortality
MH  - Humans
MH  - Infusions, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Oxygen Consumption/*drug effects/physiology
MH  - Probability
MH  - Prospective Studies
MH  - Reference Values
MH  - Risk Assessment
MH  - Survival Rate
MH  - Treatment Outcome
EDAT- 2008/01/15 09:00
MHDA- 2008/02/06 09:00
CRDT- 2008/01/15 09:00
PHST- 2006/11/09 00:00 [received]
PHST- 2007/08/14 00:00 [revised]
PHST- 2007/09/11 00:00 [accepted]
PHST- 2008/01/15 09:00 [pubmed]
PHST- 2008/02/06 09:00 [medline]
PHST- 2008/01/15 09:00 [entrez]
AID - S0735-1097(07)03363-3 [pii]
AID - 10.1016/j.jacc.2007.09.036 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2008 Jan 15;51(2):103-12. doi: 10.1016/j.jacc.2007.09.036.